[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100640682":3},{"organization":4,"armGroups":7,"interventions":16,"overallOfficials":22,"centralContacts":31,"locations":37,"responsibleParty":96,"collaborators":22,"id":98,"slug":99,"hasResults":100,"nctId":101,"briefTitle":102,"officialTitle":103,"acronym":104,"eligibilityCriteria":105,"healthyVolunteers":100,"sex":106,"minAge":107,"maxAge":22,"enrollmentInfo":108,"targetDuration":22,"studyType":111,"phases":112,"briefSummary":114,"conditions":115,"keywords":117,"overallStatus":121,"whyStopped":22,"lastUpdateSubmitDate":122,"lastUpdatePostDateStruct":123,"startDateStruct":126,"completionDateStruct":128,"leadSponsor":130,"locationsCount":131},{"fullName":5,"class":6},"Institute of Hematology & Blood Diseases Hospital, China","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Orelabrutinib Tafasitamab Lenalidomide","EXPERIMENTAL","Orelabrutinib tafasitamab Lenalidomide",[13,14,15],"Drug: Orelabrutinib","Drug: Tafasitamab","Drug: Lenalidomide",[17,23,27],{"type":18,"name":19,"description":20,"armGroupLabels":21,"otherNames":22},"DRUG","Orelabrutinib","Orelabrutinib 150 mg orally once daily on Days 1-28 of each 28-day cycle during induction therapy and maintenance therapy.",[9],null,{"type":18,"name":24,"description":25,"armGroupLabels":26,"otherNames":22},"Tafasitamab","Tafasitamab 12 mg\u002Fkg administered by intravenous infusion on Days 1, 4, 8, 15, and 22 in Cycle 1; on Days 1, 8, 15, and 22 in Cycles 2-3; and on Days 1 and 15 from Cycle 4 onward during induction therapy.",[9],{"type":18,"name":28,"description":29,"armGroupLabels":30,"otherNames":22},"Lenalidomide","Lenalidomide 20 mg orally once daily on Days 1-21 of each 28-day cycle during induction therapy and 10 mg orally once daily on Days 1-21 of each 28-day cycle during maintenance therapy.",[9],[32],{"name":33,"role":34,"phone":35,"phoneExt":22,"email":36},"Shuhua Yi, Dr","CONTACT","+86-022-23909106","yishuhua@ihcams.ac.cn",[38,54,64,74,87],{"facility":39,"status":22,"city":40,"state":41,"zip":22,"country":42,"countryCode":43,"cosmosGeoPoint":44,"geoPoint":49,"contacts":50},"Shenzhen Second People's Hospital","Shenzhen","Guangdong","China","CN",{"type":45,"coordinates":46},"Point",[47,48],114.0683,22.54554,{"lat":48,"lon":47},[51],{"name":52,"role":34,"phone":53,"phoneExt":22,"email":22},"xiaoqing Li","18620385718",{"facility":55,"status":22,"city":56,"state":57,"zip":58,"country":42,"countryCode":43,"cosmosGeoPoint":59,"geoPoint":63,"contacts":22},"Henan Cancer Hospital","Zhengzhou","Henan","450000",{"type":45,"coordinates":60},[61,62],113.64861,34.75778,{"lat":62,"lon":61},{"facility":65,"status":22,"city":66,"state":67,"zip":68,"country":42,"countryCode":43,"cosmosGeoPoint":69,"geoPoint":73,"contacts":22},"The First Affiliated Hospital of Nanchang University","Nanchang","Jiangxi","330000",{"type":45,"coordinates":70},[71,72],115.85306,28.68396,{"lat":72,"lon":71},{"facility":75,"status":22,"city":76,"state":77,"zip":22,"country":42,"countryCode":43,"cosmosGeoPoint":78,"geoPoint":82,"contacts":83},"Qilu Hospital of Shandong Province","Jinan","Shandong",{"type":45,"coordinates":79},[80,81],116.99722,36.66833,{"lat":81,"lon":80},[84],{"name":85,"role":34,"phone":86,"phoneExt":22,"email":22},"jingjing Ye","18560086995",{"facility":5,"status":22,"city":88,"state":89,"zip":90,"country":42,"countryCode":43,"cosmosGeoPoint":91,"geoPoint":95,"contacts":22},"Tianjin","Tianjin Municipality","300020",{"type":45,"coordinates":92},[93,94],117.17667,39.14222,{"lat":94,"lon":93},{"type":97,"investigatorFullName":22,"investigatorTitle":22,"investigatorAffiliation":22,"oldNameTitle":22,"oldOrganization":22},"SPONSOR","100640682","phase-2-a-exploratory-study-on-untreated-follicular-lymphoma-with-orelabrutinib-tafasitamab-and-lenalidomide-100640682",false,"NCT07585747","A Exploratory Study on Untreated Follicular Lymphoma With Orelabrutinib, Tafasitamab, and Lenalidomide","A Multicenter Exploratory Clinical Study on the Treatment of Untreated Follicular Lymphoma With Orelabrutinib, Tafasitamab, and Lenalidomide","CUREMZL002","Inclusion Criteria:\n\n1. Age \\> 18 years, regardless of gender;\n2. Newly diagnosed patients with follicular lymphoma (Grade 1, 2, or 3a) confirmed histologicallyaccording to the World Health Organization (WHO) classification of diseases;\n3. Deemed by the investigator to have an indication for treatment and require therapy;\n4. ECOG performance status score of 0-2;\n5. Laboratory tests meeting the following criteria:\n\n   1. Bone marrow hematopoietic function is essentially normal: WBC 3.5x10\\^9\u002FL, ANC \\> 1.0x10\\^9\u002FL, PLT \\> 75x10\\^9\u002FL, Hb \\> 80 g\u002FL;\n   2. Liver function: AST\u002FALT s 2xULN, TBILI s 2xULN;\n   3. Renal function: Creatinine clearance rate \\> 50 ml\u002Fmin;6. Presence of at least one measurable lesion: Lymph node lesion with a long diameter \\> 1.5 cm orextranodal lesion with a long diameter \\> 1.0 cm as shown by PET\u002FCT, CT, or MRl, or a lesion \\> 2cm assessed by clinical examination;\n\n7\\. Ability to provide written informed consent.\n\nExclusion Criteria:\n\n1. Women with a positive serum pregnancy test or who are breastfeeding;\n2. Patients with lymphoma involving the central nervous system (CNS);\n3. Clinically significant heart disease, including unstable angina, acute myocardial infarction within6 months prior to randomization, congestive heart failure with New York Heart Association(NYHA) functional class IIl or IV, or left ventricular ejection fraction \\\u003C50%;\n4. Patients with grade \\>2 neuropathy;\n5. Patients with active hepatitis B (HBV, hepatitis C (HCV, or other acquired\u002Fcongenitalimmunodeficiency diseases;\n6. Patients with severe active infections requiring systemic antibiotic treatment;\n7. Patients with a history of severe neurological or psychiatric disorders that impair trialparticipation, including dementia, epilepsy, severe depression, and mania;8. Drug abuse, or medical, psychological, or social conditions that may interfere with studyparticipation or result evaluation;\n\n9\\. Patients deemed ineligible by the investigator.","ALL","18 Years",{"count":109,"type":110},27,"ESTIMATED","INTERVENTIONAL",[113],"PHASE2","Evaluate the efficacy and safety of orelabrutinib, tafasitamab, and lenalidomide in the first-line treatment of patients with follicular lymphoma.",[116],"Follicular Lymphoma",[118,119,120],"lenalidomide","tafasitamab","orelabrutinib","NOT_YET_RECRUITING","2026-05-10",{"date":124,"type":125},"2026-05-14","ACTUAL",{"date":127,"type":110},"2026-04-15",{"date":129,"type":110},"2030-12-31",{"name":5,"class":6},5]